This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases.
The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population.
The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.
Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
For more information on this report, fill the form @http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
Intravenous Immunoglobulin (IVIG) Market: Segmentation
Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.
Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.
Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape
The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453